MHE Week in Review – Humira Dose De-escalation, 5 Drugs With Unsupported Price Increases and More

CMS has balked at covering vagus nerve stimulation for treatment-resistant depression. Positive results from an industry-sponsored randomized trial could break the logjam, although it may be several years before results are reported.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

In 2023, there was lower net spending and prices on adalimumab, which was likely because of rebates from AbbVie, Humira’s manufacturer, a new analysis finds.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.